DARMSTADT, Germany & NEW YORK - Wednesday, November 4th 2015 [ME NewsWire]

    Trial marks second Phase III study of avelumab in non-small cell lung cancer (NSCLC) initiated by Merck and Pfizer in just over six months
    Primary endpoint is progression-free survival in previously untreated patients with recurrent or Stage IV programmed death-ligand 1 positive (PD-L1+) NSCLC

(BUSINESS WIRE)-- Not intended for UK-based media

Merck and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naïve advanced NSCLC setting. The study, JAVELIN Lung 100, is designed to assess the safety and efficacy of avelumab compared with platinum-based doublet chemotherapy, in patients with late-stage NSCLC who have not previously received any treatment for their systemic lung cancer. Avelumab (previously known as MSB0010718C) is an investigational fully ... Read more »

PARIS - Wednesday, November 4th 2015 [ME NewsWire]

(BUSINESS WIRE)-- The TRIGO Group, an international provider of operational quality solutions headquartered in Paris, France, and The PIC Group, a North American leader of 3rd party quality solutions, have joined forces. The PIC Group, headquartered out of Ontario Canada with locations in Canada, USA, and Mexico, has been servicing the automotive and manufacturing industries for over 30 years. The merger between the two companies will create the largest and most comprehensive breadth of quality services being offered globally in the market today.

As these two market leaders merge, a single global provider of quality services will be created with geographic coverage second to none. With over $230 Million in annual sales, a strong financial balance sheet, and a seasoned workforce recognized for their know-how and expertise in quality systems and controls, they are well positioned to dominate the marketplace internation ... Read more »

NATIONAL HARBOR, Md. - Thursday, November 5th 2015 [ME NewsWire]

(BUSINESS WIRE)-- Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, announced today the release of 6 new monoclonal antibodies (mAb) for tumor immunology research. This announcement was made at the 30th annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD November 4-8th, 2015.

CST has released PD-L2 (D7U8C) XP® Rabbit mAb #82723, PD-L1 (Extracellular Domain Specific) (E1J2J) Rabbit mAb #15165, PD-L1 (405.9A11) Mouse mAb #29122, PD-1 (EH33) Mouse mAb #43248, TIM-3 (D5D5R) XP® Rabbit mAb #45208, and IDO (D5J4E) Rabbit mAb #86630. Each of these antibodies has been validated according to CST’s stringent standards to recognize their specific immune regulatory target by immunohistochemistry.

These antibodies add to a growing portfolio of tumor immunology products that includes the first to market, human-specific, IHC-approved VI ... Read more »